TELA (TELA Bio) Additional Paid-In Capital : $343.08 Mil(As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is TELA Bio Additional Paid-In Capital?

TELA Bio's quarterly additional paid-in capital increased from Mar. 2024 ($340.81 Mil) to Jun. 2024 ($341.90 Mil) and increased from Jun. 2024 ($341.90 Mil) to Sep. 2024 ($343.08 Mil).

TELA Bio's annual additional paid-in capital increased from Dec. 2021 ($250.06 Mil) to Dec. 2022 ($288.36 Mil) and increased from Dec. 2022 ($288.36 Mil) to Dec. 2023 ($339.66 Mil).

TELA Bio Additional Paid-In Capital Historical Data

The historical data trend for TELA Bio's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TELA Bio Additional Paid-In Capital Chart

TELA Bio Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

198.83

245.74

250.06

288.36

339.66

TELA Bio Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Additional Paid-In Capital	Get a 7-Day Free Trial															338.39	339.66	340.81	341.90	343.08

TELA Bio Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

TELA Bio Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of TELA Bio's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

TELA Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » TELA Bio Inc (NAS:TELA) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Great Valley Parkway, Suite 24, Malvern, PA, USA, 19355

Website

https://www.telabio.com

TELA Bio Inc is a United States-based medical technology company. The company is involved in developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. Its reinforced tissue matrices called OviTex improve the clinical outcomes and reduce costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. The company's second portfolio of products, the OviTex PRS Reinforced Tissue Matrix, addresses unmet needs in plastic and reconstructive surgery.

Executives

Gregory A. Firestone	officer: Chief Business Officer	C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Roberto Cuca	officer: COO and CFO	C/O TREVENA, INC., 1018 WEST 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Paul Talmo	officer: Chief Strategic Officer	C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Antony Koblish	director, officer: Chief Executive Officer	C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Orbimed Advisors Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Iv Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Opaleye Management Inc.	10 percent owner	ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Ew Healthcare Partners Fund 2-a, L.p.	other: See footnotes 1 and 2	280 PARK AVENUE, 27TH FLOOR EAST, NEW YORK NY 10017
Quaker Bioventures Ii Lp	10 percent owner	QUAKER BIOVENTURES, 2929 ARCH STREET, PHILADELPHIA PA 19104
Quaker Bioventures Capital Ii, L.p.	10 percent owner	CIRA CENTER, 2929 ARCH STREET, PHILADELPHIA PA 19104
Lisa N Colleran	director	0NE MILLENIUM WAY, BRANCHBURG NJ 08876
John Nosenzo	director	C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Federica F. O'brien	director	C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Kurt Azarbarzin	director	C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Douglas G Evans	director	1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355